- Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients with a Spinal Cord Injury
Clinical Trial
Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients with a Spinal Cord Injury
Pain below the level of the lesion is a common and serious problem in patients with a spinal cord injury (SCI). This project will test the safety of an investigational new drug for neuropathic pain, EC5026.
Eligibility Criteria
- INCLUSION: 1. Adults age 18 years or older with a complete or incomplete traumatic T6-T12 spinal cord injury (SCI), or an incomplete, non-traumatic, degenerative SCI at any spinal level, for at least 12 months and are non-ventilator-dependent. 2. Have below-level neuropathic pain related to the SCI that meets protocol-defined daily pain scores before study enrollment, and have failed at least 2 classes of medications for the SCI-related neuropathic pain. EXCLUSION: 1. Presence of other chronic pain, neuropathic or otherwise, which could confound evaluation of pain response to the medication used in the study. 2. Use of protocol-prohibited medications/treatments or presence/history of protocol-prohibited conditions.
RESEARCH. INNOVATION. DISCOVERY.